RU2013123720A - Моноклональные антитела против белка rgm a и их применение - Google Patents
Моноклональные антитела против белка rgm a и их применение Download PDFInfo
- Publication number
- RU2013123720A RU2013123720A RU2013123720/10A RU2013123720A RU2013123720A RU 2013123720 A RU2013123720 A RU 2013123720A RU 2013123720/10 A RU2013123720/10 A RU 2013123720/10A RU 2013123720 A RU2013123720 A RU 2013123720A RU 2013123720 A RU2013123720 A RU 2013123720A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- seq
- rgm
- binding
- cdr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
Abstract
1. Выделенное моноклональное антитело, содержащее антигенсвязующий домен, где указанное антитело способно связывать эпитоп молекулы RGM, указанный антигенсвязующий домен содержит по меньшей мере два набора CDR вариабельного домена, где указанные по меньшей мере два набора CDR вариабельного домена представляют собой набор VH 8D1 и набор VL 8D1, где наборы CDR вариабельного домена состоят из:2. Антитело по п. 1, содержащее набор вариабельного домена, где по меньшей мере одни из указанных трех CDR является модифицированной аминокислотной последовательностью CDR с последовательностью, которая по меньшей мере на 50% идентична исходной последовательности, где указанное антитело способно связываться с эпитопом молекулы RGM.3. Антитело по любому из предыдущих пунктов, дополнительно содержащее акцепторную каркасную область человека, где указанная акцепторная каркасная область человека содержит по меньшей мере одну аминокислотную последовательность, выбранную из группы, состоящей из SEQ ID NO:15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 и 33.4. Антитело по п. 1 или 2, которое представляет собой антитело 8D1.5. Антигенсвязующий фрагмент выделенного моноклонального антитела по любому из пп. 1-4.6. Выделенная нуклеиновая кислота, кодирующая молекулу антитела по любому из пп. 1-5.7. Вектор, содержащий выделенную нуклеиновую кислоту по п. 6.8. Клетка-хозяин, содержащая вектор по п. 7.9. Способ получения белка, способного связываться с RGM, включающий культивирование клетки-хозяина по п. 8 в культуральной среде в условиях, подходящих для получения связывающего белка, способного связываться с RGM.10. Фармацевтическая композиция для лечения заболевания, в котором акт
Claims (13)
1. Выделенное моноклональное антитело, содержащее антигенсвязующий домен, где указанное антитело способно связывать эпитоп молекулы RGM, указанный антигенсвязующий домен содержит по меньшей мере два набора CDR вариабельного домена, где указанные по меньшей мере два набора CDR вариабельного домена представляют собой набор VH 8D1 и набор VL 8D1, где наборы CDR вариабельного домена состоят из:
2. Антитело по п. 1, содержащее набор вариабельного домена, где по меньшей мере одни из указанных трех CDR является модифицированной аминокислотной последовательностью CDR с последовательностью, которая по меньшей мере на 50% идентична исходной последовательности, где указанное антитело способно связываться с эпитопом молекулы RGM.
3. Антитело по любому из предыдущих пунктов, дополнительно содержащее акцепторную каркасную область человека, где указанная акцепторная каркасная область человека содержит по меньшей мере одну аминокислотную последовательность, выбранную из группы, состоящей из SEQ ID NO:15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 и 33.
4. Антитело по п. 1 или 2, которое представляет собой антитело 8D1.
5. Антигенсвязующий фрагмент выделенного моноклонального антитела по любому из пп. 1-4.
6. Выделенная нуклеиновая кислота, кодирующая молекулу антитела по любому из пп. 1-5.
7. Вектор, содержащий выделенную нуклеиновую кислоту по п. 6.
8. Клетка-хозяин, содержащая вектор по п. 7.
9. Способ получения белка, способного связываться с RGM, включающий культивирование клетки-хозяина по п. 8 в культуральной среде в условиях, подходящих для получения связывающего белка, способного связываться с RGM.
10. Фармацевтическая композиция для лечения заболевания, в котором активность RGM A оказывает негативное воздействие, содержащая терапевтически эффективное количество антитела по любому из пп. 1-5, и фармацевтически приемлемый носитель.
11. Применение антитела по любому из пп. 1-5 для получения лекарственного средства, используемого для снижения связывания hRGM A с костным морфогентическим белком-2 и костным морофгенетическим белком-4 (BMP-2 и BMP-4) у больного.
12. Применение продукта по любому из пп. 1-5 для получения лекарственного средства для снижения активности RGM A у больного, страдающего заболеванием, при котором активность RGM A является патологической.
13. Применение по п. 12, где заболевание включает неврологические заболевания, выбранные из группы, включающей боковой амиотрофический склероз, повреждение плечевого сплетения, повреждение головного мозга, в том числе травматическое повреждение головного мозга, церебральный паралич, болезнь Гийена-Барре, лейкодистрофию, рассеянный склероз, поствакцинальный полиомиелит, расщелину позвоночника, повреждение спинного мозга, спинально-мышечную атрофию, спинальные опухоли, инсульт, поперечный миелит; деменцию, сенильную деменцию, когнитивные нарушения умеренной степени, деменцию, связанную с болезнью Альцгеймера, хорею Хантингтона, позднюю дискинезию, гиперкинезий, мании, болезнь Паркинсона, синдром Стила-Ричардсона, синдром Дауна, тяжелую псевдопаралитическую миастению, травму нерва, сосудистый амилоидоз, кровоизлияние в головной мозг I степени с амилоидозом, воспаление головного мозга, острое нарушение со спутанностью сознания, боковой амиотрофический склероз, глаукому и болезнь Альцгеймера.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3270708P | 2008-02-29 | 2008-02-29 | |
| US61/032,707 | 2008-02-29 | ||
| US9074308P | 2008-08-21 | 2008-08-21 | |
| US61/090,743 | 2008-08-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010139886/10A Division RU2524136C2 (ru) | 2008-02-29 | 2009-02-27 | Моноклональные антитела против белка rgm а и их применение |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013123720A true RU2013123720A (ru) | 2014-11-27 |
Family
ID=40626883
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010139886/10A RU2524136C2 (ru) | 2008-02-29 | 2009-02-27 | Моноклональные антитела против белка rgm а и их применение |
| RU2013123720/10A RU2013123720A (ru) | 2008-02-29 | 2013-05-23 | Моноклональные антитела против белка rgm a и их применение |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010139886/10A RU2524136C2 (ru) | 2008-02-29 | 2009-02-27 | Моноклональные антитела против белка rgm а и их применение |
Country Status (31)
| Country | Link |
|---|---|
| US (5) | US8962803B2 (ru) |
| EP (3) | EP3309173A1 (ru) |
| JP (7) | JP5661474B2 (ru) |
| KR (2) | KR101681910B1 (ru) |
| AR (1) | AR070709A1 (ru) |
| AU (1) | AU2009218693B2 (ru) |
| BR (2) | BR122012004341B1 (ru) |
| CA (2) | CA2715456C (ru) |
| CL (2) | CL2009000459A1 (ru) |
| CO (1) | CO6311003A2 (ru) |
| CR (2) | CR20170015A (ru) |
| DK (1) | DK2260055T3 (ru) |
| DO (2) | DOP2010000258A (ru) |
| EC (1) | ECSP10010481A (ru) |
| ES (1) | ES2549959T3 (ru) |
| GT (1) | GT201000249AA (ru) |
| HK (1) | HK1254184A1 (ru) |
| IL (2) | IL207787A (ru) |
| MX (1) | MX2010009505A (ru) |
| MY (1) | MY159596A (ru) |
| NZ (2) | NZ587198A (ru) |
| PE (2) | PE20140848A1 (ru) |
| PH (1) | PH12013502068A1 (ru) |
| PL (1) | PL2260055T3 (ru) |
| PT (1) | PT2260055E (ru) |
| RU (2) | RU2524136C2 (ru) |
| SG (1) | SG10201607301XA (ru) |
| TW (2) | TWI508741B (ru) |
| UY (1) | UY31677A1 (ru) |
| WO (1) | WO2009106356A1 (ru) |
| ZA (1) | ZA201208539B (ru) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002231736A1 (en) | 2000-12-22 | 2002-07-08 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Use of repulsive guidance molecule (rgm) and its modulators |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| AU2006272555B2 (en) | 2005-07-25 | 2012-03-08 | Aptevo Research And Development Llc | B-cell reduction using CD37-specific and CD20-specific binding molecules |
| CN101277974A (zh) * | 2005-09-30 | 2008-10-01 | 阿伯特有限及两合公司 | 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途 |
| EP2033971A1 (de) * | 2007-09-06 | 2009-03-11 | Abbott GmbH & Co. KG | Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung |
| CA2704357C (en) | 2007-11-02 | 2016-06-21 | Novartis Ag | Improved nogo-a binding molecules and pharmaceutical use thereof |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| NZ603059A (en) | 2008-04-11 | 2014-07-25 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| EP2282769A4 (en) * | 2008-04-29 | 2012-04-25 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
| KR20110016959A (ko) * | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| EP2297209A4 (en) | 2008-06-03 | 2012-08-01 | Abbott Lab | IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF |
| US8822645B2 (en) * | 2008-07-08 | 2014-09-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| PH12012501070A1 (en) * | 2009-12-08 | 2017-08-23 | Abbott Gmbh & Co Kg | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
| KR102284780B1 (ko) * | 2009-12-09 | 2021-08-02 | 미쓰비시 타나베 파마 코퍼레이션 | T 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 t 세포 활성화 저해 물질의 스크리닝 방법 |
| KR20130100118A (ko) | 2010-08-03 | 2013-09-09 | 아비에 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| US9046513B2 (en) | 2010-08-26 | 2015-06-02 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| CN104136462B (zh) | 2011-12-14 | 2017-06-09 | 艾伯维德国有限责任两合公司 | 用于诊断和治疗铁相关病症的组合物和方法 |
| MX357708B (es) * | 2011-12-14 | 2018-07-20 | Abbvie Deutschland | Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro. |
| AR089529A1 (es) | 2011-12-30 | 2014-08-27 | Abbvie Inc | Proteinas de union especificas duales dirigidas contra il-13 y/o il-17 |
| US9140695B2 (en) | 2012-01-18 | 2015-09-22 | University Of Utah Research Foundation | Methods for analysis of free and autoantibody-bound biomarkers and associated compositions, devices, and systems |
| AU2013211939C1 (en) | 2012-01-27 | 2018-06-07 | AbbVie Deutschland GmbH & Co. KG | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration |
| US9663569B2 (en) | 2012-06-14 | 2017-05-30 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Use of blocking agents of bone morphogenic protein (BMP) signalling for the treatment of neuroinflammatory and neurodegenerative diseases |
| PE20151179A1 (es) | 2012-11-01 | 2015-09-12 | Abbvie Inc | Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas |
| AU2014227732A1 (en) | 2013-03-15 | 2015-09-17 | Abbvie Inc. | Dual specific binding proteins directed against IL-1 beta and IL-17 |
| US20160271230A1 (en) * | 2013-09-17 | 2016-09-22 | University Health Network (Uhn): Technology Development And Commercialization | Agents directed against a cis rgma/neogenin interaction or lipid rafts and use of the same in methods of treatment |
| WO2016038084A1 (en) | 2014-09-10 | 2016-03-17 | AbbVie Deutschland GmbH & Co. KG | Rgma fragment based diagnostic assay |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
| CA2983898A1 (en) * | 2015-04-28 | 2016-11-03 | Mitsubishi Tanabe Pharma Corporation | Rgma binding protein and use thereof |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
| CA3004830A1 (en) | 2015-11-11 | 2017-05-18 | Opi Vi- Ip Holdco Llc | Composition and methods for anti-tnfr2 antibodies |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| JP7431750B2 (ja) | 2018-04-30 | 2024-02-15 | 武田薬品工業株式会社 | カンナビノイド受容体1型(cb1)結合性タンパク質及びその使用 |
| AU2019301336B2 (en) | 2018-07-10 | 2022-11-24 | Mitsubishi Tanabe Pharma Corporation | Prevention or treatment method for peripheral neuropathy or pain accompanying disease in which peripheral neuropathy or astrocyte disorder is recognized |
| PE20260298A1 (es) | 2018-07-19 | 2026-02-10 | Univ School St Marianna Medicine | Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo de tratamiento del ham |
| AR120898A1 (es) | 2019-12-26 | 2022-03-30 | Univ Osaka | Agente para tratar o prevenir neuromielitis óptica en fase aguda |
| WO2021145432A1 (ja) | 2020-01-15 | 2021-07-22 | 国立大学法人大阪大学 | 糖尿病性自律神経障害の予防又は治療剤 |
| MX2022008588A (es) | 2020-01-15 | 2022-08-10 | Univ Osaka | Agente profilactico o terapeutico para demencia. |
| US12559565B2 (en) * | 2020-04-13 | 2026-02-24 | Biosion Inc. | Antibodies binding CTLA4 and uses thereof |
| ES3075793T3 (en) | 2020-05-13 | 2026-08-07 | Disc Medicine Inc | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| AU2021273014A1 (en) | 2020-05-13 | 2022-11-17 | AbbVie Deutschland GmbH & Co. KG | Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease |
| KR102962538B1 (ko) * | 2020-11-12 | 2026-05-08 | 오르가노 코포레이션 | 금속 불순물 함유량의 분석 방법 |
| CN120152741A (zh) | 2022-11-07 | 2025-06-13 | 国立大学法人大阪大学 | 异常蛋白的聚集体蓄积所参与的疾病的预防或治疗剂 |
| JPWO2025070749A1 (ru) | 2023-09-29 | 2025-04-03 | ||
| CN118304274A (zh) * | 2024-03-28 | 2024-07-09 | 重庆医科大学附属第一医院 | 一种小胶质细胞膜伪装的声磁响应纳米粒及其制备方法和应用 |
Family Cites Families (345)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2128208A (en) | 1937-02-27 | 1938-08-23 | Du Pont | Alkoxy derivatives of methacrylic acid esters and method of producing them |
| US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| EP0092918B1 (en) | 1982-04-22 | 1988-10-19 | Imperial Chemical Industries Plc | Continuous release formulations |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| DE3587814T2 (de) | 1985-03-30 | 1994-11-10 | Marc Ballivet | Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren. |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5635600A (en) | 1986-07-07 | 1997-06-03 | Trustees Of Dartmouth College | Bifunctional and heteroantibodies specific for the high affinity Fc receptor for immunoglobulin G on human mononuclear phagocytes |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| DE3750503T2 (de) | 1986-10-22 | 1995-02-09 | Abbott Lab | Chemilumineszierende Acridinium- und Phenantridiniumsalze. |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| ATE115999T1 (de) | 1987-12-15 | 1995-01-15 | Gene Shears Pty Ltd | Ribozyme. |
| US5006309A (en) | 1988-04-22 | 1991-04-09 | Abbott Laboratories | Immunoassay device with liquid transfer between wells by washing |
| US5089424A (en) | 1988-06-14 | 1992-02-18 | Abbott Laboratories | Method and apparatus for heterogeneous chemiluminescence assay |
| DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| CA1340323C (en) | 1988-09-20 | 1999-01-19 | Arnold E. Hampel | Rna catalyst for cleaving specific rna sequences |
| US5241070A (en) | 1988-09-26 | 1993-08-31 | Ciba Corning Diagnostics Corp. | Nucleophilic polysubstituted aryl acridinium esters and uses thereof |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| GB8826530D0 (en) | 1988-11-12 | 1988-12-14 | Ped Capacitors Ltd | Electrical capacitors |
| US5063081A (en) | 1988-11-14 | 1991-11-05 | I-Stat Corporation | Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
| GB8901334D0 (en) | 1989-01-21 | 1989-03-15 | Oakland Design Products Ltd | Improvements relating to broadhead arrows |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
| CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
| EP0478627A4 (en) | 1989-05-16 | 1992-08-19 | William D. Huse | Co-expression of heteromeric receptors |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| AU6430190A (en) | 1989-10-10 | 1991-05-16 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
| US5139400A (en) | 1989-10-11 | 1992-08-18 | Ide Russell D | Progressive cavity drive train |
| CA2071867A1 (en) | 1989-11-06 | 1991-05-07 | Edith Mathiowitz | Method for producing protein microspheres |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| FR2656431B1 (fr) | 1989-12-22 | 1994-06-10 | Essilor Int | Procede et solution pour decontaminer une lentille souple, en particulier du type hydrophile. |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| CA2048302A1 (en) | 1990-08-15 | 1992-02-16 | Victoria P. Meucci | Solubilization reagent for biological test samples |
| US5135875A (en) | 1990-08-15 | 1992-08-04 | Abbott Laboratories | Protein precipitation reagent |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| CA2072758A1 (en) | 1990-09-14 | 1992-03-15 | Kenneth Francis Buechler | Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| GB9101134D0 (en) | 1991-01-18 | 1991-02-27 | R B S | Improvements in and relating to accommodation for animals |
| DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| AU1772992A (en) | 1991-04-10 | 1992-11-17 | Biosite Diagnostics Incorporated | Crosstalk inhibitors and their uses |
| EP0579767B1 (en) | 1991-04-11 | 2000-08-23 | Biosite Diagnostics Inc. | Novel conjugates and assays for simultaneous detection of multiple ligands |
| JPH06507404A (ja) | 1991-05-01 | 1994-08-25 | ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン | 感染性の呼吸性疾患の治療方法 |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| CA2069530A1 (en) | 1991-06-03 | 1992-12-04 | Cass J. Grandone | Reagent pack for immunoassays |
| JPH07503124A (ja) | 1991-06-14 | 1995-04-06 | ゾーマ・コーポレーション | 微生物によって生産される抗体断片とそれらの複合体 |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| WO1993011794A1 (en) | 1991-12-13 | 1993-06-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| GB9201755D0 (en) | 1992-01-28 | 1992-03-11 | British Bio Technology | Compounds |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5352803A (en) | 1992-03-30 | 1994-10-04 | Abbott Laboratories | 5(6)-methyl substituted fluorescein derivatives |
| EP0649533B1 (en) | 1992-03-30 | 2000-05-10 | Abbott Laboratories | Reagents and methods for the detection and quantification of thyroxine in fluid samples |
| US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
| US6019944A (en) | 1992-05-21 | 2000-02-01 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membranes |
| AU4501093A (en) | 1992-07-10 | 1994-01-31 | Horst Warneke | Assembly line for producing steel coffers for ceiling and/wall constructions from sheet metal plates |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| JP3626187B2 (ja) | 1993-06-07 | 2005-03-02 | バイカル インコーポレイテッド | 遺伝子治療に適するプラスミド |
| US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
| US5565352A (en) | 1993-11-24 | 1996-10-15 | Arch Development Corporation | Deubiquitinating enzyme: compositions and methods |
| JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| ES2201097T3 (es) | 1994-01-31 | 2004-03-16 | Trustees Of Boston University | Bibliotecas de anticuerpos policlonales. |
| JPH09510201A (ja) | 1994-03-07 | 1997-10-14 | メダレツクス・インコーポレーテツド | 臨床的効用を有する二重特異性分子 |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5541109A (en) | 1994-04-19 | 1996-07-30 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Expression cloning of c-src SH3-domain binding proteins |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| ES2210306T3 (es) | 1994-07-20 | 2004-07-01 | The General Hospital Corporation | Sistemas de trampa para interacciones, para detectar interacciones de proteinas. |
| US6111166A (en) | 1994-09-19 | 2000-08-29 | Medarex, Incorporated | Transgenic mice expressing human Fcα and β receptors |
| WO1996013518A1 (en) | 1994-10-27 | 1996-05-09 | Genentech, Inc. | Al-1 neurotrophic factor, a ligand for an eph-related tyrosine kinase receptor |
| GB9425232D0 (en) | 1994-12-14 | 1995-02-08 | Secr Defence | Method of authenticating watermarked paper |
| ATE252894T1 (de) | 1995-01-05 | 2003-11-15 | Univ Michigan | Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung |
| US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| AU705616B2 (en) | 1995-04-21 | 1999-05-27 | Cell Genesys, Inc. | Generation of large genomic DNA deletions |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| CA2225460A1 (en) | 1995-06-23 | 1997-01-09 | Winston Campbell Patterson | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
| US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| AU710347B2 (en) | 1995-08-31 | 1999-09-16 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| US5747262A (en) | 1995-10-16 | 1998-05-05 | The Regents Of The University Of California | Neurological drug screens |
| US20020136725A1 (en) | 1996-01-17 | 2002-09-26 | Smithkline Beecham Corporation | Antithrombotic agents |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| ATE239041T1 (de) | 1996-02-09 | 2003-05-15 | Basf Ag | Humane antikörper welche an humanen tnfalpha binden |
| US5985320A (en) | 1996-03-04 | 1999-11-16 | The Penn State Research Foundation | Materials and methods for enhancing cellular internalization |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| FR2754461B1 (fr) | 1996-10-16 | 1999-02-12 | Husson Olivier | Fixation demontable manuellement pour patin en ligne avec une jambiere de maintien qui commande un systeme de freinage |
| US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| ATE289353T1 (de) | 1996-12-11 | 2005-03-15 | Bristol Myers Squibb Co | Prokaryotisches zwei-hybrid system |
| US6017517A (en) | 1996-12-18 | 2000-01-25 | The Dial Corporation | Method for treating human nails |
| DE69732306T2 (de) | 1997-01-16 | 2006-01-12 | Massachusetts Institute Of Technology, Cambridge | Zubereitung von partikelhaltigen arzneimitteln zur inhalation |
| IL131016A (en) | 1997-01-21 | 2004-12-15 | Gen Hospital Corp | Selection of proteins using RNA-protein blends |
| US7368531B2 (en) | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
| WO2001054708A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | 22 human secreted proteins |
| US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
| EP0985033A4 (en) | 1997-04-04 | 2005-07-13 | Biosite Inc | POLYVALENT AND POLYCLONAL LIBRARIES |
| WO1998049286A2 (en) | 1997-05-01 | 1998-11-05 | Board Of Regents, The University Of Texas System | Directed evolution of enzymes and antibodies |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| IT1294449B1 (it) | 1997-07-02 | 1999-03-24 | F B C Di Giuliano Frati & C Sn | Struttura calzabile sportiva e metodi per attuare la stessa in particolare per pattini monofilari e da shortracking. |
| US6440455B1 (en) | 1997-09-02 | 2002-08-27 | Children's Medical Center Corporation | Methods for modulating the axonal outgrowth of central nervous system neurons |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| WO1999028349A2 (en) | 1997-12-02 | 1999-06-10 | Medarex, Inc. | CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS |
| US6464686B1 (en) | 1998-01-21 | 2002-10-15 | Abbott Laboratories | Polyurethane feeding tube and associated adaptors |
| KR20010034554A (ko) | 1998-03-03 | 2001-04-25 | 레이몬드, 엠. 위티 | 치료제로서의 cd147 결합 분자 |
| AU3214099A (en) | 1998-04-03 | 1999-10-25 | Curagen Corporation | Lyst protein complexes and lyst interacting proteins |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| TWI242563B (en) | 1998-04-30 | 2005-11-01 | Tanox Inc | Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor |
| ES2198922T3 (es) | 1998-06-24 | 2004-02-01 | Advanced Inhalation Research, Inc. | Particulas porosas grandes emitadas por un inhalador. |
| WO2000002911A2 (en) | 1998-07-10 | 2000-01-20 | Curagen Corporation | INTERACTION OF HUMAN BETA AMYLOID PRECURSOR PROTEIN (β-APP) WITH HUMAN LON-PROTEASE LIKE PROTEIN (HSLON) |
| IL128017A0 (en) | 1998-07-22 | 1999-11-30 | Technion Res & Dev Foundation | Method for detecting protein-protein interactions and a kit therefor |
| JP2002522063A (ja) | 1998-08-17 | 2002-07-23 | アブジェニックス インコーポレイテッド | 増加した血清半減期を有する改変された分子の生成 |
| WO2000014271A1 (en) | 1998-09-03 | 2000-03-16 | Loma Linda University | METHOD FOR STUDYING PROTEIN INTERACTIONS $i(IN VIVO) |
| EP1115734A4 (en) | 1998-09-24 | 2004-07-21 | Univ Duke | METHOD FOR MEASURING PROTEIN-PROTEIN INTERACTIONS IN LIVING CELLS |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| AU1728800A (en) | 1998-11-18 | 2000-06-05 | Genentech Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| ES2706547T3 (es) | 1998-12-23 | 2019-03-29 | Pfizer | Anticuerpos monoclonales humanos para CTLA-4 |
| US6231768B1 (en) | 1999-01-19 | 2001-05-15 | Nalco Chemical Company | Rheology modification of settled solids in mineral processing |
| BR0009323A (pt) | 1999-03-25 | 2002-01-08 | Knoll Gmbh | Anticorpos humanos que ligam a il-12 humana e métodos para a produção |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| WO2000073801A2 (en) | 1999-05-28 | 2000-12-07 | Ludwig Institute For Cancer Research | Breast, gastric and prostate cancer associated antigens and uses therefor |
| EP1130094A3 (en) | 1999-07-08 | 2001-11-21 | Helix Research Institute | Primers for synthesizing full length cDNA clones and their use |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7119165B2 (en) | 2000-01-12 | 2006-10-10 | Yale University | Nogo receptor-mediated blockade of axonal growth |
| SK12942002A3 (sk) | 2000-02-10 | 2003-05-02 | Abbott Laboratories | Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia |
| AU2001238677A1 (en) | 2000-02-28 | 2001-09-12 | Idec Pharmaceuticals Corporation | Method for preparing anti-mif antibodies |
| US6800455B2 (en) | 2000-03-31 | 2004-10-05 | Scios Inc. | Secreted factors |
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| EP1278778A2 (en) | 2000-05-03 | 2003-01-29 | Amgen Inc., | Modified peptides, comprising an fc domain, as therapeutic agents |
| AU2001274888A1 (en) | 2000-05-19 | 2001-12-03 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| US7029872B2 (en) | 2000-06-28 | 2006-04-18 | Glycofi, Inc | Methods for producing modified glycoproteins |
| US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
| PE20020132A1 (es) | 2000-06-29 | 2002-03-04 | Abbott Lab | Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos |
| WO2002006829A2 (en) | 2000-07-18 | 2002-01-24 | Correlogic Systems, Inc. | A process for discriminating between biological states based on hidden patterns from biological data |
| ATE360068T1 (de) | 2000-11-06 | 2007-05-15 | Cancer Rec Tech Ltd | Bildgebende verfahren, diagnose und behandlung von krankheiten |
| AU2002231736A1 (en) | 2000-12-22 | 2002-07-08 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Use of repulsive guidance molecule (rgm) and its modulators |
| EP1345968A2 (en) | 2000-12-28 | 2003-09-24 | Altus Biologics Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| US20060084794A1 (en) | 2001-04-12 | 2006-04-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US6890763B2 (en) | 2001-04-30 | 2005-05-10 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1350 daltons |
| EP1270044A3 (en) | 2001-06-18 | 2003-03-12 | Pfizer Limited | Wound healing biomarkers |
| WO2003004615A2 (en) | 2001-07-05 | 2003-01-16 | Incyte Genomics, Inc. | Secreted proteins |
| WO2003016466A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
| WO2003020894A2 (en) | 2001-08-31 | 2003-03-13 | Joslin Diabetes Center, Inc. | Insulin related transcription factor and uses thereof |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20030186374A1 (en) | 2001-10-01 | 2003-10-02 | Hufton Simon E. | Multi-chain eukaryotic display vectors and uses thereof |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US7265212B2 (en) | 2001-12-03 | 2007-09-04 | Amgen Fremont Inc. | Anti-CD45RB antibodies |
| US8435529B2 (en) | 2002-06-14 | 2013-05-07 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
| US7419821B2 (en) | 2002-03-05 | 2008-09-02 | I-Stat Corporation | Apparatus and methods for analyte measurement and immunoassay |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| US6864239B2 (en) | 2002-03-27 | 2005-03-08 | Theratechnologies Inc. | Methods and compounds for prevention and treatment of elevated intraocular pressure and related conditions |
| WO2003089608A2 (en) | 2002-04-18 | 2003-10-30 | The General Hospital Corporation | Drg11-responsive (dragon) gene family |
| US6989100B2 (en) | 2002-05-09 | 2006-01-24 | Ppd Biomarker Discovery Sciences, Llc | Methods for time-alignment of liquid chromatography-mass spectrometry data |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| JP2005534650A (ja) | 2002-06-11 | 2005-11-17 | ザ バーナム インスティテュート | エリスロポイエチンおよびインスリン様増殖因子の神経保護的相乗作用 |
| CA2542171C (en) | 2002-06-26 | 2015-12-15 | Abbott Gmbh & Co. Kg | Modulators and modulation of the interaction between rgm and neogenin |
| EP1380644A1 (en) | 2002-07-08 | 2004-01-14 | Kylix B.V. | The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role |
| US20040018577A1 (en) | 2002-07-29 | 2004-01-29 | Emerson Campbell John Lewis | Multiple hybrid immunoassay |
| AR040778A1 (es) | 2002-08-06 | 2005-04-20 | Glaxo Group Ltd | Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina). |
| US7541440B2 (en) | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
| US20050058649A1 (en) | 2002-12-02 | 2005-03-17 | Landes Gregory M. | Antibodies directed to phospholipase A2 and uses thereof |
| AU2003299581A1 (en) | 2002-12-02 | 2004-06-23 | Abgenix, Inc. | Antibodies against drugs of abuse |
| EP1440981A3 (en) | 2003-01-21 | 2005-11-23 | Research Association for Biotechnology | Full-length human cdna |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| EP2330213A1 (en) | 2003-03-05 | 2011-06-08 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| GB0306309D0 (en) | 2003-03-19 | 2003-04-23 | Glaxo Group Ltd | Method of treatment |
| EP1618131A2 (en) | 2003-04-15 | 2006-01-25 | Xenon Pharmaceuticals Inc. | Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof |
| PT2829283T (pt) | 2003-04-30 | 2017-09-08 | Univ Zuerich | Método para tratamento do cancro utilizando uma imunotoxina |
| EA008253B1 (ru) * | 2003-08-07 | 2007-04-27 | Байоджен Айдек Ма Инк. | Антагонисты nogo-рецептора |
| JP2007501612A (ja) | 2003-08-07 | 2007-02-01 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Nogo受容体アンタゴニスト |
| CN1838968A (zh) | 2003-08-08 | 2006-09-27 | 艾伯吉尼斯公司 | 针对甲状旁腺激素(pth)之抗体和其用途 |
| US20060003391A1 (en) | 2003-08-11 | 2006-01-05 | Ring Brian Z | Reagents and methods for use in cancer diagnosis, classification and therapy |
| US20050042664A1 (en) | 2003-08-22 | 2005-02-24 | Medimmune, Inc. | Humanization of antibodies |
| US7723099B2 (en) | 2003-09-10 | 2010-05-25 | Abbott Point Of Care Inc. | Immunoassay device with immuno-reference electrode |
| US7682833B2 (en) | 2003-09-10 | 2010-03-23 | Abbott Point Of Care Inc. | Immunoassay device with improved sample closure |
| CA2545756A1 (en) | 2003-11-07 | 2005-05-26 | Curagen Corporation | Antibodies against secretoryleukocyte protease inhibitor |
| NZ548013A (en) * | 2003-12-22 | 2009-04-30 | Glaxo Group Ltd | Immunoglobulins |
| WO2005061554A1 (ja) | 2003-12-24 | 2005-07-07 | Idemitsu Kosan Co., Ltd. | ポリオレフィンの製造方法及びその製造装置 |
| US20110171126A1 (en) | 2010-01-11 | 2011-07-14 | Center For Molecular Medicine And Immunology | Enhanced Cytotoxicity of Anti-CD74 and Anti-HLA-DR Antibodies with Interferon-Gamma |
| WO2005087268A1 (ja) | 2004-03-11 | 2005-09-22 | Bioclues, Inc | 軸索再生促進剤 |
| JP2007535317A (ja) | 2004-04-15 | 2007-12-06 | グライコフィ, インコーポレイテッド | 下等真核生物におけるガラクトシル化された糖タンパク質の産生 |
| US20060063208A1 (en) | 2004-08-02 | 2006-03-23 | Woolf Clifford J | DRG11-responsive (DRAGON) gene and uses thereof |
| WO2006021955A2 (en) | 2004-08-23 | 2006-03-02 | Mor Research Applications Ltd. | Use of bat monoclonal antibody for immunotherapy |
| EP1781824A2 (en) | 2004-08-25 | 2007-05-09 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
| US7919093B2 (en) | 2004-11-16 | 2011-04-05 | Trustees Of Boston University | Roles for dual endothelin-1/angiotensin II receptor (Dear) in hypertension and angiogenesis |
| EP2322206A3 (fr) | 2004-11-22 | 2013-06-05 | Centre National de la Recherche Scientifique | Nétrine 1 mutée, ses fragments et leur utilisation comme médicaments |
| US20060257396A1 (en) | 2004-12-15 | 2006-11-16 | Jacobsen Jack S | Abeta antibodies for use in improving cognition |
| EP1677113A1 (en) | 2004-12-29 | 2006-07-05 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Method for the identification of protein-protein interactions in disease related protein networks |
| EP2954903A1 (en) | 2005-02-16 | 2015-12-16 | The General Hospital Corporation | Use of bmp antagonists to regulate hepcidin-mediated iron metabolism |
| KR20080021585A (ko) | 2005-03-05 | 2008-03-07 | 애보트 게엠베하 운트 콤파니 카게 | 스크리닝 방법, 비확산성 a-베타 올리고머의 정제 방법,당해 비확산성 a-베타 올리고머에 대한 선택적 항체 및당해 항체의 제조 방법 |
| US7504225B2 (en) | 2005-05-12 | 2009-03-17 | Applied Genomics, Inc. | Reagents and methods for use in cancer diagnosis, classification and therapy |
| WO2006127861A2 (en) | 2005-05-25 | 2006-11-30 | Expression Pathology, Inc. | Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations |
| SI1904104T1 (sl) | 2005-07-08 | 2013-12-31 | Biogen Idec Ma Inc. | Protitelesa SP35 in njihova uporaba |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| KR20140053410A (ko) | 2005-08-19 | 2014-05-07 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| CN101277974A (zh) | 2005-09-30 | 2008-10-01 | 阿伯特有限及两合公司 | 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途 |
| WO2007042809A2 (en) | 2005-10-11 | 2007-04-19 | Domantis Limited | Antibody polypeptide library screening and selected antibody polypeptides |
| US8865763B2 (en) | 2005-10-14 | 2014-10-21 | Alltech, Inc. | Methods and compositions for altering cell function |
| US20080004255A1 (en) | 2005-10-14 | 2008-01-03 | Alltech, Inc. | Methods and compositions for altering cell function |
| US8871715B2 (en) | 2005-10-14 | 2014-10-28 | Alltech, Inc. | Use of selenium compounds, especially selenium yeasts for altering cognitive function |
| US20070155687A1 (en) | 2005-10-14 | 2007-07-05 | Alltech, Inc. | Methods and compositions for altering cell function |
| JP2009514555A (ja) | 2005-11-08 | 2009-04-09 | ユークリッド ダイアグノスティックス リミテッド ライアビリティー カンパニー | 癌評価の遺伝子関連CpGアイランドのメチル化アッセイのための材料と方法 |
| WO2007058671A1 (en) | 2005-11-21 | 2007-05-24 | West Michael D | Novel uses of cells with prenatal patterns of gene expression |
| RU2442793C2 (ru) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ |
| AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| US7420040B2 (en) | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| DK1991275T3 (en) | 2006-03-08 | 2014-12-08 | Archemix Llc | Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES |
| WO2007106507A2 (en) | 2006-03-14 | 2007-09-20 | Petrie Howard T | Detection of gene expression in mixed sample or tissue |
| EP1865071A1 (en) | 2006-06-09 | 2007-12-12 | Rheinische Friedrich-Wilhelms-Universität Bonn | Method for early diagnosis of proliferative diabetic retinopathy |
| US7883855B2 (en) | 2006-07-21 | 2011-02-08 | Abbott Laboratories | Immunosuppressant drug extraction reagent for immunoassays |
| EP2052089A4 (en) | 2006-07-28 | 2010-05-05 | Chundsell Medicals Ab | EMBRYONIC STEM CELL MARKERS FOR CANCER DIAGNOSIS AND PROGNOSIS |
| WO2008038599A1 (en) | 2006-09-25 | 2008-04-03 | National University Corporation Chiba University | Axonal regeneration promoter |
| US8066154B2 (en) | 2006-10-02 | 2011-11-29 | Norman Schmidt | Device for controlled metering of semi solid food products |
| CA2607490C (en) | 2006-10-18 | 2018-04-10 | Norman G. Schmidt | Device to allow for cleaning access in semi-solid metering machines |
| US20100036091A1 (en) | 2006-11-10 | 2010-02-11 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| WO2008133722A2 (en) * | 2006-11-10 | 2008-11-06 | Ucb Pharma S.A. | Anti human sclerostin antibodies |
| CA2987970A1 (en) | 2006-11-21 | 2008-05-29 | Abbvie Inc. | Neutralizing monoclonal antibodies against the nogo-66 receptor (ngr) and uses thereof |
| EP2102341A2 (en) | 2006-12-08 | 2009-09-23 | Asuragen, INC. | Mirna regulated genes and pathways as targets for therapeutic intervention |
| WO2008073919A2 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mir-20 regulated genes and pathways as targets for therapeutic intervention |
| KR101343916B1 (ko) | 2006-12-21 | 2013-12-20 | 삼성전자주식회사 | 폐암의 림프절 미세전이 진단용 마커, 상기 마커에 대한프라이머를 포함하는 키트, 상기 마커 또는 상기 마커에대한 항체를 포함하는 마이크로어레이, 및 폐암의 림프절미세전이 여부를 진단하는 방법 |
| WO2008082651A2 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Dual-specific il-1a/ il-1b antibodies |
| US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
| EP1947114A1 (en) | 2007-01-19 | 2008-07-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Mutated netrin 4, fragments thereof and uses thereof as drugs |
| CA2679381A1 (en) * | 2007-02-28 | 2008-09-04 | Schering Corporation | Engineered anti-il-23r antibodies |
| WO2008119565A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific binding domain |
| US7906293B2 (en) | 2007-04-09 | 2011-03-15 | Abbott Laboratories | Acridinium phenyl esters useful in the analysis of biological |
| WO2008127735A1 (en) | 2007-04-13 | 2008-10-23 | Stemline Therapeutics, Inc. | Il3ralpha antibody conjugates and uses thereof |
| WO2009002386A2 (en) | 2007-05-24 | 2008-12-31 | The Regents Of The University Of Californina | Size-dependent biological effect of nanoparticles |
| WO2009006543A1 (en) | 2007-07-02 | 2009-01-08 | Euclid Diagnostics Llc | Methods for evaluating the methylation status of a polynucleotide |
| US8070827B2 (en) | 2007-07-03 | 2011-12-06 | Histogenics Corporation | Method for use of a double-structured tissue implant for treatment of tissue defects |
| US20090054984A1 (en) | 2007-08-20 | 2009-02-26 | Histogenics Corporation | Method For Use Of A Double-Structured Tissue Implant For Treatment Of Tissue Defects |
| EP2182887B1 (en) | 2007-08-20 | 2016-12-14 | Histogenics Corporation | A method for improvement of differentiation of mesenchymal stem cells using a double-structured tissue implant |
| EP2033971A1 (de) | 2007-09-06 | 2009-03-11 | Abbott GmbH & Co. KG | Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung |
| US7981415B2 (en) | 2007-09-07 | 2011-07-19 | Cisthera, Inc. | Humanized PAI-1 antibodies |
| CA2701189C (en) | 2007-10-11 | 2017-05-16 | Biogen Idec Ma Inc. | Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists |
| MX2010005282A (es) | 2007-11-13 | 2010-08-31 | Teva Pharma | Anticuerpos humanizados contra tl1a. |
| GB2456390A (en) | 2008-01-15 | 2009-07-22 | Glaxo Group Ltd | Bipolar disorder treatments |
| EP2581455A3 (en) | 2008-01-17 | 2013-07-10 | Suregene LLC | Genetic markers of mental illness |
| WO2009094592A2 (en) | 2008-01-23 | 2009-07-30 | Perlegen Sciences, Inc. | Genetic basis of alzheimer's disease and diagnosis and treatment thereof |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| WO2009105624A2 (en) | 2008-02-21 | 2009-08-27 | Massachusetts Institute Of Technology | Simultaneous delivery of receptors and/or co-receptors for growth factor stability and activity |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| WO2009111375A2 (en) | 2008-03-01 | 2009-09-11 | Abraxis Bioscience, Llc | Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas |
| JP5470817B2 (ja) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | 電池用電極およびこれを用いた電池、並びにその製造方法 |
| DE102008014880A1 (de) | 2008-03-12 | 2009-09-17 | Eberhard-Karls-Universität Tübingen | Antientzündliches Polypeptid |
| WO2009129538A2 (en) | 2008-04-18 | 2009-10-22 | Xencor, Inc. | Human equivalent monoclonal antibodies engineered from nonhuman variable regions |
| WO2009140383A2 (en) | 2008-05-13 | 2009-11-19 | Archemix Corp. | Aptamers that bind to p-selectin and their use as coagulation, thrombotic, inflammatory, and metastatic disease therapeutics |
| EP2297209A4 (en) | 2008-06-03 | 2012-08-01 | Abbott Lab | IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF |
| KR20110016959A (ko) | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| US8822645B2 (en) | 2008-07-08 | 2014-09-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| WO2010006184A2 (en) | 2008-07-11 | 2010-01-14 | Emory University | Small-molecule inhibitors of hif and angiogenesis |
| WO2010006189A2 (en) | 2008-07-11 | 2010-01-14 | Emory University | Small-molecule inhibitors of hif and angiogenesis |
| US20100184033A1 (en) | 2008-07-16 | 2010-07-22 | West Michael D | Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby |
| WO2010007144A2 (en) | 2008-07-18 | 2010-01-21 | Centre National De La Recherche Scientifique | New mutated netrin 4 proteins, fragments thereof and their uses as drugs |
| EP2326356B1 (en) | 2008-08-07 | 2017-10-11 | Exogenesis Corporation | Medical device for bone implant and method for producing such a device |
| US20110201519A1 (en) | 2008-08-18 | 2011-08-18 | Sarwal Minnie M | Methods and Compositions for Determining a Graft Tolerant Phenotype in a Subject |
| MX2011003381A (es) | 2008-09-30 | 2011-04-21 | Abbott Lab | Metodo mejorado para despliegue de arn. |
| RU2011117213A (ru) | 2008-09-30 | 2012-11-10 | Эббот Лэборетриз (Us) | Улучшенные библиотеки антител |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| KR101039751B1 (ko) | 2008-10-16 | 2011-06-09 | 한국생명공학연구원 | Tmprss4―특이적인 인간항체 |
| US20110293526A1 (en) | 2008-11-20 | 2011-12-01 | University Of Southern California | Compositions and methods to modulate hair growth |
| US10927415B2 (en) | 2008-11-26 | 2021-02-23 | The Johns Hopkins University | Methods for identifying cancer risk |
| ES2602459T3 (es) | 2008-12-26 | 2017-02-21 | Kyowa Hakko Kirin Co., Ltd. | Anticuerpo anti-CD4 |
| WO2010088688A2 (en) | 2009-02-02 | 2010-08-05 | Biotheranostics, Inc. | Diagnosis of in situ and invasive breast cancer |
| US20100254979A1 (en) | 2009-03-06 | 2010-10-07 | Cisthera, Incorporated | Humanized PAI-1 Antibodies and Uses Thereof |
| WO2010105298A1 (en) | 2009-03-18 | 2010-09-23 | Simon Barry | Peptidase inhibitor 16 (pi16) as a biomarker for regulatory t (treg) cells and uses thereof |
| US20110020221A1 (en) | 2009-04-09 | 2011-01-27 | The Johns Hopkins University | Cancer stem cell expression patterns and compounds to target cancer stem cells |
| WO2010127284A2 (en) | 2009-05-01 | 2010-11-04 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
| CN102549016B (zh) | 2009-06-30 | 2015-05-06 | 研究发展基金会 | 免疫球蛋白fc多肽 |
| CA2775978A1 (en) | 2009-09-29 | 2011-04-07 | Protagen Ag | Marker sequences for pancreatic cancer diseases, pancreatic carcinoma and use thereof |
| WO2011039734A2 (en) | 2009-10-02 | 2011-04-07 | Enzo Medico | Use of genes involved in anchorage independence for the optimization of diagnosis and treatment of human cancer |
| MY173390A (en) | 2009-10-23 | 2020-01-22 | Takeda Pharmaceuticals Co | Anti-gcc antibody molecules and related compositions and methods |
| CA2782620A1 (en) | 2009-12-01 | 2011-06-09 | Compendia Bioscience, Inc. | Classification of cancers |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| PH12012501070A1 (en) | 2009-12-08 | 2017-08-23 | Abbott Gmbh & Co Kg | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
| KR102284780B1 (ko) | 2009-12-09 | 2021-08-02 | 미쓰비시 타나베 파마 코퍼레이션 | T 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 t 세포 활성화 저해 물질의 스크리닝 방법 |
| AR080154A1 (es) | 2010-02-10 | 2012-03-14 | Immunogen Inc | Anticuerpos cd20 y su utilizacion |
| EP2552483A4 (en) | 2010-04-01 | 2013-09-25 | Immunomedics Inc | USE OF ANTIBODIES TO REDUCE THE NUMBER OF CELLS CONTAINING ANTIGENS AND DENDRITIC CELLS |
| JP5987537B2 (ja) * | 2012-08-03 | 2016-09-07 | 日産自動車株式会社 | 走行支援装置及び走行支援方法 |
| JP6136279B2 (ja) | 2013-01-15 | 2017-05-31 | 株式会社ジェイテクト | 転がり軸受装置 |
| TWI503850B (zh) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | 過電流保護元件 |
| TWI510996B (zh) | 2013-10-03 | 2015-12-01 | Acer Inc | 控制觸控面板的方法以及使用該方法的可攜式電腦 |
| US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
-
2009
- 2009-02-20 US US12/389,927 patent/US8962803B2/en active Active
- 2009-02-26 UY UY031677A patent/UY31677A1/es not_active Application Discontinuation
- 2009-02-27 KR KR1020107021295A patent/KR101681910B1/ko not_active Expired - Fee Related
- 2009-02-27 TW TW098106619A patent/TWI508741B/zh not_active IP Right Cessation
- 2009-02-27 SG SG10201607301XA patent/SG10201607301XA/en unknown
- 2009-02-27 KR KR1020167020260A patent/KR20160091457A/ko not_active Ceased
- 2009-02-27 CR CR20170015A patent/CR20170015A/es unknown
- 2009-02-27 BR BR122012004341-9A patent/BR122012004341B1/pt active IP Right Grant
- 2009-02-27 PE PE2013001715A patent/PE20140848A1/es not_active Application Discontinuation
- 2009-02-27 PL PL09715176T patent/PL2260055T3/pl unknown
- 2009-02-27 PT PT97151765T patent/PT2260055E/pt unknown
- 2009-02-27 CA CA2715456A patent/CA2715456C/en active Active
- 2009-02-27 EP EP17204022.2A patent/EP3309173A1/en not_active Withdrawn
- 2009-02-27 MY MYPI2010003873A patent/MY159596A/en unknown
- 2009-02-27 RU RU2010139886/10A patent/RU2524136C2/ru active
- 2009-02-27 NZ NZ587198A patent/NZ587198A/xx not_active IP Right Cessation
- 2009-02-27 EP EP15177075.7A patent/EP2995625B1/en not_active Not-in-force
- 2009-02-27 EP EP09715176.5A patent/EP2260055B1/en active Active
- 2009-02-27 CA CA3090849A patent/CA3090849A1/en active Pending
- 2009-02-27 NZ NZ602256A patent/NZ602256A/en not_active IP Right Cessation
- 2009-02-27 CL CL2009000459A patent/CL2009000459A1/es unknown
- 2009-02-27 AR ARP090100700A patent/AR070709A1/es active IP Right Grant
- 2009-02-27 BR BRPI0908012-0A2A patent/BRPI0908012A2/pt active Search and Examination
- 2009-02-27 WO PCT/EP2009/001437 patent/WO2009106356A1/en not_active Ceased
- 2009-02-27 TW TW104130646A patent/TW201545760A/zh unknown
- 2009-02-27 JP JP2010548035A patent/JP5661474B2/ja not_active Expired - Fee Related
- 2009-02-27 AU AU2009218693A patent/AU2009218693B2/en not_active Ceased
- 2009-02-27 ES ES09715176.5T patent/ES2549959T3/es active Active
- 2009-02-27 DK DK09715176.5T patent/DK2260055T3/en active
- 2009-02-27 PE PE2009000315A patent/PE20091474A1/es active IP Right Grant
- 2009-02-27 MX MX2010009505A patent/MX2010009505A/es active IP Right Grant
-
2010
- 2010-08-24 IL IL207787A patent/IL207787A/en active IP Right Grant
- 2010-08-24 DO DO2010000258A patent/DOP2010000258A/es unknown
- 2010-09-13 EC EC2010010481A patent/ECSP10010481A/es unknown
- 2010-09-23 CO CO10117825A patent/CO6311003A2/es active IP Right Grant
- 2010-09-27 CR CR11691A patent/CR11691A/es unknown
-
2012
- 2012-11-13 ZA ZA2012/08539A patent/ZA201208539B/en unknown
- 2012-12-17 GT GT201000249AK patent/GT201000249AA/es unknown
-
2013
- 2013-04-12 DO DO2013000081A patent/DOP2013000081A/es unknown
- 2013-05-13 IL IL226343A patent/IL226343A0/en unknown
- 2013-05-23 RU RU2013123720/10A patent/RU2013123720A/ru not_active Application Discontinuation
- 2013-10-04 PH PH12013502068A patent/PH12013502068A1/en unknown
- 2013-11-12 CL CL2013003244A patent/CL2013003244A1/es unknown
-
2014
- 2014-02-24 JP JP2014032545A patent/JP5986123B2/ja not_active Expired - Fee Related
-
2015
- 2015-01-07 US US14/591,445 patent/US9605069B2/en not_active Expired - Fee Related
-
2016
- 2016-03-16 JP JP2016051959A patent/JP2016175897A/ja active Pending
- 2016-12-23 US US15/389,627 patent/US20170166633A1/en not_active Abandoned
-
2017
- 2017-08-04 JP JP2017151514A patent/JP2018021041A/ja active Pending
- 2017-12-05 US US15/832,177 patent/US20180162933A1/en not_active Abandoned
-
2018
- 2018-10-18 HK HK18113321.3A patent/HK1254184A1/en unknown
-
2019
- 2019-10-03 JP JP2019182721A patent/JP2020018316A/ja active Pending
-
2020
- 2020-09-09 US US17/015,442 patent/US20210230260A1/en not_active Abandoned
-
2021
- 2021-11-05 JP JP2021180878A patent/JP2022036944A/ja active Pending
-
2023
- 2023-04-17 JP JP2023066952A patent/JP2023103237A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010139886A (ru) | Моноклональные антитела против белка rgm а и их применение | |
| RU2010150348A (ru) | Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применение | |
| RU2006123481A (ru) | Nogo-a-нейтрализующие иммуноглобулины для лечения неврологических заболеваний | |
| RU2495050C2 (ru) | Связующий элемент для рецептора gm-csf | |
| EP4289857A1 (en) | Drug conjugate of glucocorticoid receptor agonist, and application thereof in medicine | |
| TW202218683A (zh) | 使用trem2促效劑治療與群落刺激因子1受體功能障礙相關之疾病 | |
| RU2008126242A (ru) | Антитела против глобуломера а бета, их антигенсвязывающие части, соответствующие гибридомы, нуклеиновые кислоты, векторы, клетки-хозяева, способы получения указанных антител, композиции, содержащие указанные антитела, применения указанных антител и способы использования указанных антител | |
| RU2007132020A (ru) | Партнеры специфического связывания с ngf | |
| RU2010133892A (ru) | Гуманизированные моноклональные антитела против человеческого nkg2a | |
| CA2494008A1 (en) | Anti-myelin associated glycoprotein (mag) antibodies | |
| RU2013155906A (ru) | Антитела анти-angptl3 и их применение | |
| RU2012119788A (ru) | Связывающие il-1 белки | |
| RU2019140602A (ru) | АНТИ-GARP-TGF-β-АНТИТЕЛА | |
| RU2013143358A (ru) | Анти-fgfr4 антитела и способы их применения | |
| CN101653604A (zh) | 抗ngf抗体用于治疗各种疾病 | |
| RU2015118180A (ru) | Антитела к бета-амилоиду | |
| RU2021117293A (ru) | АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| RU2015111675A (ru) | Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами | |
| RU2007108067A (ru) | Антагонистические антитела к il-17 | |
| RU2012142311A (ru) | Интерлейкин-13-связывающие белки | |
| FI4397683T3 (fi) | Anti-ihmisen interleukiini-33 monoklonaalinen vasta-aine ja sen käyttö | |
| RU2015115956A (ru) | Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения | |
| JP2014502150A5 (ru) | ||
| RU2014117510A (ru) | Лечение ревматоидного артрита | |
| JP2023535024A5 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150120 |